Payment overview · 2025
General Payments
$618.88
34 reported records · 13 companies
Healthcare provider profile · identity verified
John M Robertson, MD
Allopathic & Osteopathic Physicians|Family Medicine · HARROGATE, TN · NPI 1881858215
Verified facts
What the public records show
CMS Open Payments records show John M Robertson, MD received $618.88 in general payments during 2025 across 34 reported records.
ABBVIE INC. accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Linzess, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 219 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $137.02 | 22.1% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $98.64 | 15.9% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $66.62 | 10.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $56.47 | 9.1% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $47.90 | 7.7% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.44 | 7.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.08 | 6.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.06 | 5.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.60 | 5.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.70 | 2.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.66 | 2.7% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $14.52 | 2.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.17 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $618.88 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $104.70 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $80.38 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $74.19 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $47.90 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $46.15 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $43.44 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $41.72 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.44 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.06 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $32.60 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $10.49 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $10.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 219 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
64 | 63 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
77 | 55 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
219 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 607 | 182 |
| Atorvastatin Calcium | Atorvastatin Calcium | 523 | 168 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 491 | 88 |
| Alprazolam | Alprazolam | 490 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 419 | 147 |
| Gabapentin | Gabapentin | 402 | 96 |
| Lisinopril | Lisinopril | 391 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 336 | 114 |
| Losartan Potassium | Losartan Potassium | 336 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 336 | 111 |
| Omeprazole | Omeprazole | 335 | 111 |
| Montelukast Sodium | Montelukast Sodium | 247 | 79 |
| Metformin Hcl | Metformin Hcl | 238 | 77 |
| Simvastatin | Simvastatin | 230 | 67 |
| Eliquis | Apixaban | 219 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 218 | 81 |
| Tramadol Hcl | Tramadol Hcl | 211 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 210 | 83 |
| Metoprolol Tartrate | Metoprolol Tartrate | 205 | 67 |
| Furosemide | Furosemide | 200 | 67 |
| Prednisone | Prednisone | 199 | 130 |
| Famotidine | Famotidine | 186 | 66 |
| Metformin Hcl Er | Metformin Hcl | 182 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 57 |
| Glimepiride | Glimepiride | 164 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 149 | 50 |
| Potassium Chloride | Potassium Chloride | 149 | 51 |
| Atenolol | Atenolol | 148 | 45 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 147 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 139 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 138 | 51 |
| Clonazepam | Clonazepam | 136 | 25 |
| Meloxicam | Meloxicam | 133 | 51 |
| Carvedilol | Carvedilol | 130 | 46 |
| Ondansetron Odt | Ondansetron | 129 | 46 |
| Allopurinol | Allopurinol | 126 | 39 |
| Cefdinir | Cefdinir | 122 | 100 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 121 | 39 |
| Pregabalin | Pregabalin | 121 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 48 |
| Alendronate Sodium | Alendronate Sodium | 117 | 34 |
| Lorazepam | Lorazepam | 108 | 18 |
| Trazodone Hcl | Trazodone Hcl | 103 | 43 |
| Celecoxib | Celecoxib | 101 | 37 |
| Azithromycin | Azithromycin | 98 | 82 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 94 | 14 |
| Mounjaro | Tirzepatide | 91 | 18 |
| Fluconazole | Fluconazole | 87 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 24 |
| Ozempic | Semaglutide | 83 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 80 | 26 |
| Jardiance | Empagliflozin | 80 | 21 |
| Glipizide | Glipizide | 78 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 77 | 26 |
| Sertraline Hcl | Sertraline Hcl | 77 | 30 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 77 | 55 |
| Benazepril Hcl | Benazepril Hcl | 72 | 23 |
| Diazepam | Diazepam | 72 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 67 | 24 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 64 | 63 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 21 |
| Buspirone Hcl | Buspirone Hcl | 62 | 29 |
| Ezetimibe | Ezetimibe | 61 | 23 |
| Donepezil Hcl | Donepezil Hcl | 57 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 57 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 24 |
| Meclizine Hcl | Meclizine Hcl | 55 | 25 |
| Bupropion Xl | Bupropion Hcl | 53 | 21 |
| Estradiol | Estradiol | 53 | 17 |
| Levofloxacin | Levofloxacin | 53 | 38 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 52 | 16 |
| Dexamethasone | Dexamethasone | 52 | 48 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 40 |
| Glyxambi | Empagliflozin/Linagliptin | 51 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 18 |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Trulicity | Dulaglutide | 47 | 11 |
| Ibuprofen | Ibuprofen | 46 | 22 |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Mirtazapine | Mirtazapine | 46 | 21 |
| Synthroid | Levothyroxine Sodium | 46 | 13 |
| Nitroglycerin | Nitroglycerin | 45 | 23 |
| Nebivolol Hcl | Nebivolol Hcl | 44 | 15 |
| Fenofibrate | Fenofibrate,micronized | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 14 |
| Promethazine Hcl | Promethazine Hcl | 41 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 19 |
| Bumetanide | Bumetanide | 40 | 12 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 40 | 12 |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 28 |
| Spironolactone | Spironolactone | 37 | 14 |
| Xarelto | Rivaroxaban | 37 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | 12 |
| Telmisartan | Telmisartan | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | 12 |
| Warfarin Sodium | Warfarin Sodium | 32 | 11 |
| Linzess | Linaclotide | 31 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | 11 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 29 | 12 |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | 11 |
| Valsartan | Valsartan | 28 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | 11 |
| Brilinta | Ticagrelor | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 12 |
| Lovastatin | Lovastatin | 26 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 20 |
| Sotalol | Sotalol Hcl | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Amoxicillin | Amoxicillin | 23 | suppressed |
| Gemtesa | Vibegron | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | 11 |
| Prasugrel Hcl | Prasugrel Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | 12 |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 14 |
| Droplet Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Modafinil | Modafinil | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 17 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | 11 |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Ofloxacin | Ofloxacin | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Eplerenone | Eplerenone | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $618.88 · 34 records | ABBVIE INC. | AIRSUPRA, CREON, Doc Band, ELIQUIS, FREESTYLE LIBRE 3, GEMTESA, LINZESS, NURTEC ODT, Ozempic, QULIPTA, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error